Hyloris releases Annual Report 2024

01 May 2025 00:21 CEST

Press Release

Regulated Information 

Hyloris releases Annual Report 2024

• Publication of the Annual Report for Financial Year 2024
• Annual Shareholders’ Meeting on Tuesday, 10^th of June 2025

Liège, Belgium – 30 April 2025, 11:55 PM CET – Regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs by enhancing and repurposing existing medications, announces the publication of its Annual Report for the financial year 2024. The annual report is available in English, with a French version to follow shortly, at https://hyloris.com/investors-toolkit/.

The Annual Report 2024 includes a chapter on Environmental, Social and Governance (ESG) matters. 

Hyloris also announces that its Annual Shareholders’ Meeting will be held on Tuesday, 10 June 2025, at 02:00 PM CET, at the Company’s registered office: Boulevard Patience & Beaujonc 3/1, 4000 Liège, Belgium. All relevant documents will be made available on the Company’s website at least one month prior to the meeting.

About Hyloris Pharmaceuticals SA

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.  

The Company’s development strategy primarily focuses on leveraging existing regulatory pathways, such as the FDA’s 505(b)2 pathway in the U.S or similar regulatory frameworks in other region which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This type of regulatory pathway can reduce the clinical burden required to bring a product to market and significantly shorten the development timelines and reduce costs and risks. 

Hyloris has built a broad, patented portfolio of 22 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Two products are currently in early phases of commercialization with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. Outside its core strategic focus, the Company also has 1 approved high barrier generic product launched in the U.S. and 2 high barrier generic products in development. 

Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

For more information, contact Hyloris:

Stijn Van Rompay, Co-CEO

Stijn.vanrompay@hyloris.com

Thomas Jacobsen, Co-CEO

thomas.jacobsen@hyloris.com

+32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.

Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

This press release contains information about a product under development and is not intended as a promotional statement. The product mentioned is subject to regulatory approval and is not currently available for sale. Please consult licensed medical professionals for healthcare decisions.

20250502-hylorisar24ensubsequent-20250430-publication.pdf